Harbor Capital Advisors Inc. Decreases Stock Position in Elanco Animal Health Incorporated $ELAN

Key Points

• Harbor Capital Advisors Inc. has reduced its holdings in Elanco Animal Health by 13.8% during the second quarter, now owning about 0.16% of the company.
• Institutional investors remain active, with significant increases in holdings from Dimensional Fund Advisors and Goldman Sachs Group, among others, demonstrating strong interest in Elanco.
• Analysts generally view Elanco favorably, with a consensus rating of "Moderate Buy" and an average price target of $17.33, indicating positive market sentiment.

Harbor Capital Advisors Inc. lowered its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 13.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 772,062 shares of the company's stock after selling 124,092 shares during the period. Harbor Capital Advisors Inc. owned 0.16% of Elanco Animal Health worth $11,025,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of ELAN. Nuveen LLC bought a new position in Elanco Animal Health in the first quarter worth approximately $115,212,000. Dimensional Fund Advisors LP lifted its holdings in Elanco Animal Health by 14.3% during the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after acquiring an additional 2,563,740 shares during the period. Goldman Sachs Group Inc. increased its holdings in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after buying an additional 2,445,872 shares during the last quarter. ASR Vermogensbeheer N.V. purchased a new stake in shares of Elanco Animal Health during the 1st quarter worth approximately $23,744,000. Finally, DDD Partners LLC raised its holdings in shares of Elanco Animal Health by 202.7% in the 1st quarter. DDD Partners LLC now owns 1,492,992 shares of the company's stock worth $15,676,000 after purchasing an additional 999,716 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELAN has been the topic of several research reports. UBS Group boosted their target price on Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Stifel Nicolaus raised their price target on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. Piper Sandler increased their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, August 11th. Finally, William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Elanco Animal Health has an average rating of "Moderate Buy" and an average price target of $17.33.

Elanco Animal Health Price Performance

Elanco Animal Health stock traded up $0.08 during midday trading on Friday, reaching $19.18. 8,550,435 shares of the stock traded hands, compared to its average volume of 10,031,933. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The stock has a market cap of $9.53 billion, a P/E ratio of 22.30, a PEG ratio of 3.54 and a beta of 1.62. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $19.26. The stock's fifty day moving average is $16.77 and its 200-day moving average is $13.45.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. Elanco Animal Health's quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.